Pharming Group (NASDAQ:PHAR – Get Free Report) and Earth Science Tech (OTCMKTS:ETST – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Risk and Volatility
Pharming Group has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500.
Profitability
This table compares Pharming Group and Earth Science Tech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharming Group | 0.71% | 1.08% | 0.59% |
| Earth Science Tech | 10.02% | 73.51% | 44.22% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharming Group | 0 | 2 | 3 | 0 | 2.60 |
| Earth Science Tech | 0 | 0 | 0 | 0 | 0.00 |
Pharming Group currently has a consensus target price of $38.33, suggesting a potential upside of 116.82%. Given Pharming Group’s stronger consensus rating and higher possible upside, research analysts plainly believe Pharming Group is more favorable than Earth Science Tech.
Institutional & Insider Ownership
0.0% of Pharming Group shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 24.9% of Earth Science Tech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Pharming Group and Earth Science Tech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharming Group | $376.13 million | 3.30 | $2.85 million | $0.01 | 1,768.00 |
| Earth Science Tech | $33.12 million | 1.05 | $3.25 million | N/A | N/A |
Earth Science Tech has lower revenue, but higher earnings than Pharming Group.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
About Earth Science Tech
Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
